动脉灌注化疗栓塞联合放射粒子植入治疗原发性肝癌患者疗效及其对肝组织TRF1和TRF2表达的影响*

doi:10.3969/j.issn.1672-5069.2019.01.032

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (1): 121-124.doi: 10.3969/j.issn.1672-5069.2019.01.032

动脉灌注化疗栓塞联合放射粒子植入治疗原发性肝癌患者疗效及其对肝组织TRF1和TRF2表达的影响^*

陈向, 汪宝林, 吴琛, 唐劲草, 张弛, 褚朝顺

210011 南京市南京医科大学第二附属医院消化医学中心

收稿日期:2017-10-30 出版日期:2019-01-10 发布日期:2019-01-16
通讯作者: 汪宝林,E-mail: aga670@163.com
作者简介:陈向,男,28岁,医学硕士。E-mail: yks170705@163.com
基金资助:
*南京医科大学校长科研基金资助项目（编号：2015NJMU033）

Efficacy of transcatheter arterial chemoembolization and radion implantation in the treatment of patients with primary liver cancer and its impact on hepatic expressions of TRF1 and TRF2

Chen Xiang, Wang Baolin, Wu Chen, et al.

Digestive Medical Center,Second Affiliated Hospital,Nanjing Medical University,Nanjing 210011

Received:2017-10-30 Online:2019-01-10 Published:2019-01-16

摘要/Abstract

摘要： 目的探讨动脉灌注化疗栓塞术（TACE）联合放射粒子植入治疗原发性肝癌（PLC）患者疗效及其对肝组织端粒重复序列结合因子（TRF）1和TRF2表达的影响。方法 2012年12月~2015年12月我院诊治的108例PLC患者,采用抛硬币法随机分为观察组54例和对照组54例。对照组接受单纯TACE治疗,观察组在TACE治疗的基础上接受¹²⁵I放射粒子植入治疗。肝穿取得肝组织,采用SP法检测肝组织TRF1和TRF2表达情况。结果在治疗3 m末,观察组客观缓解率为79.6%,显著高于对照组的61.1%（x²=4.441,P<0.05）;观察组血清CEA和AFP水平分别为（273.7±38.1） ng/ml和（820.4±130.3） μg/L,显著低于对照组的【（312.5±33.9） ng/ml和（1080.1±121.3） μg/L,P<0.01】;观察组癌旁肝组织TRF1表达量为（9.7±2.3）,显著高于癌组织的【（4.2±1.8）,P<0.01】,而观察组癌组织TRF2表达量为（9.2±2.2）,显著高于癌旁肝组织的【（3.8±2.6）,P<0.01】;观察组1 a生存率显著高于对照组[96.3%（52/54）对85.2%（46/54）,x²=3.967,P=0.046]。结论采用TACE联合放射粒子植入术治疗PLC患者安全有效,能够有效降低外周血肿瘤标志物水平,调节肝癌组织TRF1和TRF2表达,抑制肿瘤组织的生长,阻止病情进展,有利于患者康复。

关键词: 原发性肝癌, 肝动脉化疗栓塞, 放射粒子植入, 端粒重复序列结合因子

Abstract: Objective To explore the efficacy of transcatheter arterial chemoembolization （TACE） and radion implantation in the treatment of patients with primary liver cancer（PLC） and its impact on hepatic expressions of telomeric repeat binding factor（TRF）1 and TRF2. Methods 108 patients with PLC between December 2013 and December 2015 were recruited in our hospital,and were randomly divided into two groups by tossing coins. 54 patients in the control group received TACE,and another 54 in the observation group received intrahepatic¹²⁵I radion impoantation at the base of TACE. Liver biopsies were conducted and the expressions of TRF1 and TRF2 were stained by SP. Results At the end of 3 months after treatment,the Objective remission rate（ORR） in the combination group was 79.6%,much higher than 61.1% in the TACE-treated group（P<0.05）；serum CEA and AFP levels were （273.7±38.1） ng/ml and （820.4±130.3） μg/L,much lower than （312.5±33.9） ng/ml and （1080.1±121.3） μg/L,respectively,in the TACE group（P<0.01）；the TRF1 expression in the adjacent liver tissue was（9.7±2.3）,much stronger than（4.2±1.8） in the tumorous tissues（P<0.01）,while TRF2 expression in the tumorous tissue was（9.2±2.2）,much stronger than （3.8±2.6） in the adjacent tissue（P<0.01）；the 1 yr-survival in the combination group was much higher than in the TACE group（96.3% vs. 85.2%,x²=3.967,P=0.046）. Conclusion The combination of TACE and hepatic radion implantation in the treatment of patients with PLC is effective,and the mechanism by which it works might be related to the regulation of expressions of TRF1 and TRF2.

Key words: Hepatoma, Transcatheter arterial chemoembolization, Radion implantation, Telomeric repeat binding factor 1, Telomeric repeat binding factor 2

陈向, 汪宝林, 吴琛, 唐劲草, 张弛, 褚朝顺. 动脉灌注化疗栓塞联合放射粒子植入治疗原发性肝癌患者疗效及其对肝组织TRF1和TRF2表达的影响^*[J]. 实用肝脏病杂志, 2019, 22(1): 121-124.

Chen Xiang, Wang Baolin, Wu Chen, et al.. Efficacy of transcatheter arterial chemoembolization and radion implantation in the treatment of patients with primary liver cancer and its impact on hepatic expressions of TRF1 and TRF2[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 121-124.

参考文献

[1] 张伟,陈刚,孙密密,等. 经导管肝动脉化疗栓塞联合射频消融治疗PLC患者临床疗效评价. 实用肝脏病杂志,2017,20(4):472-476.
[2] 侯帅,樊琳琳,戴光荣. 非手术治疗PLC研究进展. 实用肝脏病杂志,2016,19(2):249-252.
[3] Ohki T,Sato K,Yamagami M,et al.Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan:A retrospective analysis. Clin Drug Invest,2015,35(11):1-9.
[4] Peng S,Yang QX,Zhang T,et al.Lobaplatin-TACE combined with radioactive 125I seed implantation for treatment of primary hepatocellular carcinoma. Asian Pacif J Cancer Prevent,2014,15(13):5155-5160.
[5] Huang D,Lu W,Zou S,et al.RhoGDIα is a potential prognostic biomarker and control stelomere regulationin colorectal cancer. Cancer Sci,2017,108(7):1293-1302.
[6] Chen W,Wang Y,Li F,et al.Expression of telomere repeat binding factor 1 and TRF2 in prostate cancer and correlation with clinical parameters. Bio Med Res Int,2017,2017:1-5.
[7] Bosch FX,Ribes J,Díaz M,et al.Primary liver cancer:Worldwide incidence and trends. Gastroenterology,2004,127(5):S5.
[8] Lencioni R,Llovet JM.Modified RECIST(mRECIST) assessment for hepatocellular carcinoma. Sem liver Dis,2010,30(1):52.
[9] Lee K.The interaction of ZSCAN4 with TRF1:effects on regulation of telomere elongation in cancer cells. Cancer Res,2013,73:579.
[10] Njei B,Rotman Y,Ditah I,et al.Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology,2015,61(1):191.
[11] Seki T,Tamai T,Nakagawa T,et al.Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer,2015,89(6):1245-1251.
[12] Sun L,Guo H,Jiang R,et al.Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma. Tumor Biol,2016,37(1):799-806.
[13] Yoshikawa M,Morine Y,Ikemoto T,et al.Elevated preoperative serum CEA level is associated with poor prognosis in patients with hepatocellular carcinoma through the epithelial-mesenchymal transition. Anticancer Res,2017,37(3):1169.
[14] Hou L,Joyce BT,Tao G,et al.Blood telomere length attrition and cancer development in the normative aging study cohort. Ebiomed,2015,2(6):591-596.
[15] Shay JW,Wright WE.Role of telomeres and telomerase in cancer. Eur J Cancer,2011,21(6):349-353.
[16] Oh BK,Kim YJ,Park C,et al.Up-regulation of telomere-binding proteins,TRF1,TRF2,and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis. Am J Pathol,2005,166(1):73.
[17] Bouhlel L,Ilie M,Signetti L,et al.The role of TRF2 on tumor progression in non-small cell lung cancer:potential modulating effect on myeloid cells. Cancer Res,2016,76(Supplement 14):3230.
[18] 吴发宗,纪建松,应希慧,等. 射频消融联合放射性¹²⁵I粒子植入治疗多结节型原发性肝癌疗效分析. 中华医学杂志,2016,96(9):693-696.

动脉灌注化疗栓塞联合放射粒子植入治疗原发性肝癌患者疗效及其对肝组织TRF1和TRF2表达的影响^*

Efficacy of transcatheter arterial chemoembolization and radion implantation in the treatment of patients with primary liver cancer and its impact on hepatic expressions of TRF1 and TRF2

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[2]	刘杏, 赵树立, 张殿隆. 七氟烷吸入时机对肝脏部分切除术患者肝脏缺血再灌注损伤的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 728-731.
[3]	崔发强, 李涛, 王铮, 陈青. 原发性肝癌患者外周血KRAS基因水平及其对西妥昔单克隆抗体治疗疗效的影响[J]. 实用肝脏病杂志, 2019, 22(4): 565-568.
[4]	赵晓光, 史玉洁. 应用还原型谷胱甘肽预防处理接受TACE治疗的中晚期原发性肝癌患者对肝功能的影响[J]. 实用肝脏病杂志, 2019, 22(3): 425-428.
[5]	李克田,沈明格,王凤荣,胡春荣,曹玉杰,芦鹏. 血糖水平对原发性肝癌患者¹⁸F-FDG摄取和PET/CT检查图像质量的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 256-259.
[6]	王秀清,马艳君,詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析 ^*[J]. 实用肝脏病杂志, 2019, 22(2): 260-263.
[7]	王翠晓, 高静. 血清高尔基蛋白73、甲胎蛋白异质体3、甲胎蛋白和α-L-岩藻糖苷酶水平诊断原发性肝癌的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 113-116.
[8]	闫书鸣, 王建国, 李泽信, 游焜, 王亮, 郭鹏威. 门冬氨酸鸟氨酸治疗肝癌切除术患者对肝脏缺血再灌注损伤的保护作用研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 932-935.
[9]	汪华, 赵亚宁. 索拉菲尼治疗进展期原发性肝癌患者有效性及安全性研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 936-939.
[10]	杨学民, 李朝路, 李兆阳. microRNA194过表达抑制荷瘤小鼠肝癌细胞生长的实验研究^*[J]. 实用肝脏病杂志, 2018, 21(5): 705-708.
[11]	郭振宁. 超声造影诊断微小原发性肝癌患者临床价值研究[J]. 实用肝脏病杂志, 2018, 21(5): 741-744.
[12]	伍家彬, 谢晓海. 丙泊酚对肝部分切除术治疗的原发性肝癌患者外周血淋巴细胞亚群和血清肿瘤相关标志物水平的影响[J]. 实用肝脏病杂志, 2018, 21(5): 745-748.
[13]	王全晖, 张元浩, 袁守信, 乔师师. 腹腔镜下肝部分切除术治疗原发性肝癌患者外周血T淋巴细胞亚群和血清细胞因子水平的变化^*[J]. 实用肝脏病杂志, 2018, 21(5): 753-756.
[14]	金娟, 朱守林, 高静, 袁春梅. 尊严疗法联合心理干预对终末期原发性肝癌患者负性情绪和生活质量的影响研究^*[J]. 实用肝脏病杂志, 2018, 21(5): 805-806.
[15]	杨小琴, 殷杰, 杨红生, 潘亚娟, 储开云. 以APP移动信息为基础的术前访视对原发性肝癌患者情绪的影响^*[J]. 实用肝脏病杂志, 2018, 21(5): 807-808.